|

The SAFE Prospective Registry

RECRUITINGN/ASponsored by University Hospital Ostrava
Actively Recruiting
PhaseN/A
SponsorUniversity Hospital Ostrava
Started2023-05-01
Est. completion2026-05
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05794464

Summary

Secretoneurin (SN) is a neuropeptide from the chromogranin family that influences intracellular calcium handling. SN suppresses calcium leakage from the sarcoplasmic reticulum through the ryanodine receptor. SN is a novel biomarker that has shown the potential to predict adverse arrhythmic events.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Atrial fibrillation (Afib); (paroxysmal, persistent)
* Patients indicated for catheter ablation and/or electrical cardioversion
* Signed informed consent

Exclusion Criteria:

* Longstanding or permanent atrial fibrillation
* Severe mitral regurgitation
* Heart failure with a permanently reduced ejection fraction
* Cerebral ischaemic stroke in \< 3 months
* Severe kidney injury
* Severe renal insufficiency
* Hepatic insufficiency limiting biomarker sampling
* Myocardial infarction \< 3 months

Conditions2

Atrial Fibrillation, Paroxysmal or PersistentHeart Disease

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.